FDA Approves New Risperdal Uses

By Admin on August 23, 2007 | Last updated on March 21, 2019

The U.S. Food and Drug Administration (FDA) announced that it has approved Risperdal (risperidone) for the treatment of schizophrenia in adolescents aged 13 to 17, and for short-term treatment of certain types of bipolar disorder in children and adolescents aged 10 to 17. This is the first FDA approval of an atypical antipsychotic drug to treat either disorder in these age groups. In April 2005, FDA issued an alert informing patients of the risks associated with Risperdal use, including stroke, nervous system and movement problems, high blood sugar, and diabetes.

Copied to clipboard